<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01658904</url>
  </required_header>
  <id_info>
    <org_study_id>120179</org_study_id>
    <secondary_id>12-C-0179</secondary_id>
    <nct_id>NCT01658904</nct_id>
  </id_info>
  <brief_title>Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma</brief_title>
  <official_title>Phase I / II Study Of Carfilzomib (CFZ) Intensification Early After Autologous Transplantation (AHCT) For Plasma Cell Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - Plasma cell myeloma is a type of cancer that affects the plasma cells in the bone marrow.
      It can be difficult to treat with chemotherapy. One possible treatment combines chemotherapy
      with a stem cell transplant. To make this treatment more effective, researchers want to give
      another drug along with the transplant. This drug, carfilzomib, is often used to help treat
      plasma cell myeloma. However, it is not usually given along with the transplant. Researchers
      want to see if it is safe and effective to combine the stem cell transplant with carfilzomib,
      and if it improves the results of the transplant.

      Objectives:

      - To test the safety and effectiveness of carfilzomib given with stem cell transplant for
      plasma cell myeloma.

      Eligibility:

      - Individuals between 18 and 75 years of age who are having a stem cell transplant to treat
      plasma cell myeloma.

      Design:

        -  Participants will be screened with a physical exam and medical history. Blood and urine
           samples will be collected. Imaging studies and a bone marrow biopsy will also be
           performed.

        -  Participants will have their own stem cells collected for the transplant. The transplant
           will be performed according to the standard of care.

        -  All participants will receive carfilzomib on the first 2 days after transplant. The
           study doctors will determine the number of additional doses that they may have.

        -  Treatment will be monitored with frequent blood tests and imaging studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

        -  Despite very significant progress in therapy for plasma cell myeloma (PCM) in the last
           decade, the disease remains mostly incurable.

        -  High-dose chemotherapy followed by autologous hematopoietic cell transplantation (AHCT)
           continues to be a critical component of early treatment for PCM, but it is clear that
           the disease is not eradicated by the present high-dose therapy strategy, while
           intensifying the preparative regimen has, to this day, resulted in either no improvement
           in disease control or increased toxicity.

        -  Carfilzomib (CFZ) is a newer proteasome inhibitor with increased activity and a safer
           toxicity profile than bortezomib in PCM. The favorable toxicity profile makes it a
           likely candidate for increasing anti-PCM drug exposure in the early post-AHCT period.

      Objectives:

      Primary Objectives

      -Evaluate feasibility and toxicity of an increasing number of doses of CFZ administered in
      the early period post-AHCT for PCM

      Secondary Objective

        -  Evaluate the immune reconstitution post-AHCT following CFZ therapy

        -  Evaluate the effects of the addition of CFZ in the early post-AHCT period on the
           response rate at day 100 post-AHCT

      Eligibility:

        -  Newly diagnosed subjects with PCM following induction therapy

        -  Subjects with documentation of persistent/refractory disease who have received no more
           than 2 salvage regimens following relapse and who have not undergone AHCT

        -  Adequate organ functions with no major co-morbidity

        -  Age greater than 18 years and less than or equal to 75 years

      Design:

        -  Phase I/II study on the backbone of high-dose melphalan on day -2 pre-AHCT

        -  Addition of an increasing number of doses of CFZ in the early post-AHCT period
           introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:

      Cohort 1: add CFZ 20 mg/m^2 on days +1, +2

      Cohort 2 : add CFZ 20 mg/m^2 on days: +1, +2, +8, +9

      Cohort 3: add CFZ 20 mg/m^2 on days: +1, +2, +8, +9 and add an early post-AHCT consolidation
      following

      engraftment: CFZ 20 mg/m^2 given on days 42-43 then CFZ 56 mg/m^2 given on days 49-50, 56-57,
      then on days 70-71, 77-78 and 84-85

      -Dose-limiting toxicity, incidence of engraftment failure and treatment-related mortality are
      the objects of early stopping rules for safety purposes
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    study closed prematurely because investigator left National Institutes of Health
  </why_stopped>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment Failure Transplant Related Mortality</measure>
    <time_frame>up to day 100</time_frame>
    <description>Engraftment failure is defined as the failure to achieve neutrophil engraftment by day 21; defined from day 0, day of autologous hematopoietic cell transplantation (AHCT), as the first of three consecutive days on which the patient's absolute neutrophil count is greater than 0.5x10(9)/l following the nadir. Transplant related mortality is defined as any subject who dies in the first 100 days post-AHCT of any non-relapse related cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>8 months and 15 days</time_frame>
    <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Immune Reconstitution Post-Pre-autologous Hematopoietic Cell Transplantation (AHCT) Following Carfilzomib (CFZ) Therapy</measure>
    <time_frame>Post-AHCT following CFZ therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Effects of the Addition of Carfilzomib (CFZ) in the Early Post-Pre-autologous Hematopoietic Cell Transplantation (AHCT) Period on the Response Rate at Day 100 Post-AHCT</measure>
    <time_frame>Day 100 post-AHCT</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Leukemia, Plasma Cell</condition>
  <arm_group>
    <arm_group_label>Cohort 1- CFZ 20 mg/m^2 (Day 1,2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2- CFZ 20 mg/m^2 (Day 1,2,8,9)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3-CFZ 20 mg/m^2 (Day1,2,8,9/AHCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <arm_group_label>Cohort 1- CFZ 20 mg/m^2 (Day 1,2)</arm_group_label>
    <arm_group_label>Cohort 2- CFZ 20 mg/m^2 (Day 1,2,8,9)</arm_group_label>
    <arm_group_label>Cohort 3-CFZ 20 mg/m^2 (Day1,2,8,9/AHCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <arm_group_label>Cohort 1- CFZ 20 mg/m^2 (Day 1,2)</arm_group_label>
    <arm_group_label>Cohort 2- CFZ 20 mg/m^2 (Day 1,2,8,9)</arm_group_label>
    <arm_group_label>Cohort 3-CFZ 20 mg/m^2 (Day1,2,8,9/AHCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <arm_group_label>Cohort 1- CFZ 20 mg/m^2 (Day 1,2)</arm_group_label>
    <arm_group_label>Cohort 2- CFZ 20 mg/m^2 (Day 1,2,8,9)</arm_group_label>
    <arm_group_label>Cohort 3-CFZ 20 mg/m^2 (Day1,2,8,9/AHCT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Multiple myeloma criteria for newly or recently diagnosed subjects

          -  Presence of clonal plasma cells in the bone marrow greater than or equal to 10% or a
             documented clonal plasmacytoma (either by immuno-histochemistry or by Ig gene
             rearrangement), AND

          -  Presence of an M-component; an M-component (immunoglobulin G (IgG) or immunoglobulin A
             (IgA)) in serum greater than or equal to 1g/dl or in urine greater or equal to 200
             mg/24 h.

        ALTERNATIVELY, if the M-component criterion is not met:

          -  An abnormal serum free light chain (FLC) ratio on the serum FLC assay, or if the FLC
             ratio is normal,

          -  Baseline bone marrow must have 10% or greater clonal plasma cells

        AND, IN ADDITION, presence of one or more of the following attributable to the disease (in
        the presence or absence of an M-component):

          -  Calcium elevation greater than 11.5 mg/dl (2.65 mmol/l)

          -  Renal insufficiency: serum creatinine greater than 2 mg/dl (177 mmol/l) or less than
             60ml/min.

          -  Hemoglobin less than 10 g/dl (12.5 mmol/l) or 2 g/dl (1.25 mmol/l) below lower normal

          -  Bone disease (lytic lesions or osteopenia)

          -  Other evidence of disease activity: repeated infections, secondary amyloidosis,
             hyperviscosity, hypogammablobulinemia

        Criteria for subjects with persistent or recurrent disease

        Subjects with recurrent or persistent disease are eligible if:

          -  Criteria for initiating therapy for plasma cell myeloma (PCM) had been present at the
             time of initiation of therapy or there is clear clinical indication for salvage
             therapy.

          -  They have not undergone an autologous transplant for the treatment of PCM

          -  They have received no more than two salvage regimens for the treatment of recurrent or
             persistent PCM (each regimen may include more than one cycle)

        Other eligibility criteria

        -Age &gt; 18 years and less than or equal to 75 years.

        In subjects between 65 and 75 years of age, physiologic age and co-morbidity will be
        thoroughly evaluated before enrolling. Specifically, any history of cardiovascular
        pathology or symptoms not clearly fitting the exclusion criteria of Section 2.1.2 will
        prompt an evaluation by a Clinical Center Cardiologist and eligibility will be considered
        on a case-by-case basis.

          -  Karnofsky performance status of 70% or greater (Eastern Cooperative Oncology Group
             (ECOG) 0 or 1)

          -  Ejection fraction (EF) by multi-gated acquisition scan (MUGA) or 2-D echocardiogram
             within institution normal limits. In case of low ejection fraction (EF), the subject
             may remain eligible after a stress echocardiogram is performed if the EF is more than
             35% and if the increase in EF with stress is estimated at 10% or more.

          -  creatinine clearance &gt; 25ml/min (measured on a 24 hour urine collection)

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal
             to 3 x upper limit of normal

          -  Bilirubin less than or equal to1.5 (except if due to Gilbert's disease)

          -  Corrected carbon dioxide diffusing capacity (DLCO) greater than or equal to 40% on
             pulmonary function tests

        EXCLUSION CRITERIA:

          -  Prior allogeneic or autologous stem cell transplantation

          -  Prior treatment with Carfilzomib (CFZ) is not an exclusion

          -  History of recent (&lt; 6 months) cerebrovascular accident

          -  History of documented recent (&lt; 6 months) pulmonary embolus

          -  Clinically significant cardiac pathology:

          -  Myocardial infarction within 6 months prior to enrollment,

          -  Class III or IV heart failure according to New York Heart Association (NYHA),

          -  Uncontrolled angina,

          -  Severe uncontrolled ventricular arrhythmias, or

          -  Electrocardiographic evidence of acute ischemia or active conduction abnormalities
             felt to pose a significant cardiac riks by a Cardiology consultant

          -  Patients with a history of coronary artery bypass grafting or angioplasty will receive
             a cardiology evaluation and be considered on a case-by-case basis.

          -  Human immunodeficiency virus (HIV) seropositive

          -  Acute active infection requiring treatment (systemic antibiotics, antivirals, or
             antifungals) within 14 days prior to enrollment

          -  Active hepatitis B or C infection

          -  Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment

          -  Major surgery within 21 days prior to enrollment

          -  Non-hematologic malignancy within the past 3 years with the exception of a) adequately
             treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b)
             carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or
             less with stable prostate-specific antigen levels; or d) cancer considered cured by
             surgical resection or unlikely to impact survival during the duration of the study,
             such as localized transitional cell carcinoma of the bladder or benign tumors of the
             adrenal or pancreas

          -  Significant neuropathy (Grades 3 4, or Grade 2 with pain) within 14 days prior to
             randomization

          -  Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize
             CFZ)

          -  Patients known or found to be pregnant

          -  Female patients of childbearing age who are unwilling to practice contraception

          -  Patients may be excluded at the discretion of the principal investigator (PI) if it is
             deemed that allowing participation would represent an unacceptable medical or
             psychiatric risk.

          -  Patients must be able to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald E Gress, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.</citation>
    <PMID>18287387</PMID>
  </reference>
  <reference>
    <citation>Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006 Jan 20;24(3):431-6. Epub 2005 Dec 19.</citation>
    <PMID>16365178</PMID>
  </reference>
  <reference>
    <citation>Tosi P, Zamagni E, Cellini C, Plasmati R, Cangini D, Tacchetti P, Perrone G, Pastorelli F, Tura S, Baccarani M, Cavo M. Neurological toxicity of long-term (&gt;1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol. 2005 Mar;74(3):212-6.</citation>
    <PMID>15693790</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2012</study_first_submitted>
  <study_first_submitted_qc>August 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2012</study_first_posted>
  <results_first_submitted>October 14, 2015</results_first_submitted>
  <results_first_submitted_qc>February 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 3, 2016</results_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Daniel Fowler, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Autologous Transplant</keyword>
  <keyword>Proteasome Inhibitor</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Filgrastim</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study did not progress to the phase II portion. The study was closed prematurely because the investigator left the National Institutes of Health.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1- CFZ 20 mg/m^2 (Day 1,2)</title>
          <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2- CFZ 20 mg/m^2 (Day 1,2,8,9)</title>
          <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3-CFZ 20 mg/m^2 (Day1,2,8,9/AHCT)</title>
          <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Principal Investigator discretion</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1- CFZ 20 mg/m^2 (Day 1,2)</title>
          <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2- CFZ 20 mg/m^2 (Day 1,2,8,9)</title>
          <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3-CFZ 20 mg/m^2 (Day1,2,8,9/AHCT)</title>
          <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.6" spread="10.39"/>
                    <measurement group_id="B4" value="49.6" spread="10.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Engraftment Failure Transplant Related Mortality</title>
        <description>Engraftment failure is defined as the failure to achieve neutrophil engraftment by day 21; defined from day 0, day of autologous hematopoietic cell transplantation (AHCT), as the first of three consecutive days on which the patient's absolute neutrophil count is greater than 0.5x10(9)/l following the nadir. Transplant related mortality is defined as any subject who dies in the first 100 days post-AHCT of any non-relapse related cause.</description>
        <time_frame>up to day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1- CFZ 20 mg/m^2 (Day 1,2)</title>
            <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2- CFZ 20 mg/m^2 (Day 1,2,8,9)</title>
            <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3-CFZ 20 mg/m^2 (Day1,2,8,9/AHCT)</title>
            <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.</description>
          </group>
        </group_list>
        <measure>
          <title>Engraftment Failure Transplant Related Mortality</title>
          <description>Engraftment failure is defined as the failure to achieve neutrophil engraftment by day 21; defined from day 0, day of autologous hematopoietic cell transplantation (AHCT), as the first of three consecutive days on which the patient's absolute neutrophil count is greater than 0.5x10(9)/l following the nadir. Transplant related mortality is defined as any subject who dies in the first 100 days post-AHCT of any non-relapse related cause.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
        <time_frame>8 months and 15 days</time_frame>
        <population>Analysis of dose limiting toxicities (DLTs) was planned but not performed due to study termination; this Outcome Measure captures any events that occurred.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1- CFZ 20 mg/m^2 (Day 1,2)</title>
            <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2- CFZ 20 mg/m^2 (Day 1,2,8,9)</title>
            <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3-CFZ 20 mg/m^2 (Day1,2,8,9/AHCT)</title>
            <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
          <population>Analysis of dose limiting toxicities (DLTs) was planned but not performed due to study termination; this Outcome Measure captures any events that occurred.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate the Immune Reconstitution Post-Pre-autologous Hematopoietic Cell Transplantation (AHCT) Following Carfilzomib (CFZ) Therapy</title>
        <time_frame>Post-AHCT following CFZ therapy</time_frame>
        <population>This outcome measure was not done because the study was closed prematurely because the investigator left the National Institutes of Health.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1- CFZ 20 mg/m^2 (Day 1,2)</title>
            <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.
Carfilzomib
Melphalan
Filgrastim</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2- CFZ 20 mg/m^2 (Day 1,2,8,9)</title>
            <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.
Carfilzomib
Melphalan
Filgrastim</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3-CFZ 20 mg/m^2 (Day1,2,8,9/AHCT)</title>
            <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.
Carfilzomib
Melphalan
Filgrastim</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Immune Reconstitution Post-Pre-autologous Hematopoietic Cell Transplantation (AHCT) Following Carfilzomib (CFZ) Therapy</title>
          <population>This outcome measure was not done because the study was closed prematurely because the investigator left the National Institutes of Health.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate the Effects of the Addition of Carfilzomib (CFZ) in the Early Post-Pre-autologous Hematopoietic Cell Transplantation (AHCT) Period on the Response Rate at Day 100 Post-AHCT</title>
        <time_frame>Day 100 post-AHCT</time_frame>
        <population>This outcome measure was not done because the study was closed prematurely because the investigator left the National Institutes of Health.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1- CFZ 20 mg/m^2 (Day 1,2)</title>
            <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2- CFZ 20 mg/m^2 (Day 1,2,8,9)</title>
            <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3-CFZ 20 mg/m^2 (Day1,2,8,9/AHCT)</title>
            <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Effects of the Addition of Carfilzomib (CFZ) in the Early Post-Pre-autologous Hematopoietic Cell Transplantation (AHCT) Period on the Response Rate at Day 100 Post-AHCT</title>
          <population>This outcome measure was not done because the study was closed prematurely because the investigator left the National Institutes of Health.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1- CFZ 20 mg/m^2 (Day 1,2)</title>
          <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2- CFZ 20 mg/m^2 (Day 1,2,8,9)</title>
          <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3-CFZ 20 mg/m^2 (Day1,2,8,9/AHCT)</title>
          <description>Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was closed prematurely because the investigator left the National Institutes of Health.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ronald Gress</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>301-496-1791</phone>
      <email>gressr@dc10a.nci.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

